Building the Factory at Home

Tariff pressure and a pricing deal touched off the largest onshoring push the obesity-drug industry has seen. The story of these drugs is increasingly a story about where they get made.

The pricing agreements of late 2025 came bundled with a second, quieter story: the physical plants that produce these medicines. In exchange for tariff relief, the two giants of the obesity market pledged to expand American manufacturing on a scale that reshapes their supply chains. GLP-1 manufacturing has become a strategic front in its own right.

The scale of the commitments

Eli Lilly announced at least $27 billion in new U.S. manufacturing investment. Novo Nordisk added roughly $10 billion, some of it earmarked to produce its oral semaglutide tablet end-to-end on American soil. The logic runs two ways at once — political cover under a tariff regime that threatened imported pharmaceuticals, and practical capacity for a demand curve that keeps bending upward.

Both drivers are real. The administration’s tariff threats made domestic production a hedge against cost shocks. And the sheer volume of GLP-1 demand — tens of millions of patients, weekly or daily dosing — turns supply into an existential constraint. A drug no one can manufacture at scale is a drug patients cannot get.

Why peptide manufacturing is genuinely hard

Part of why these medicines went into shortage in the first place is how difficult they are to make. Peptide drugs like semaglutide require multi-step synthesis, specialized fill-finish lines, and the tricky business of loading precise doses into pens and vials at industrial scale. Capacity cannot be conjured overnight; a new plant takes years to design, build, validate, and bring online.

That difficulty also explains a strategic shift toward small molecules. Orforglipron, a non-peptide GLP-1 pill, is cheaper and simpler to produce than a peptide. This manufacturing advantage shaped its low launch pricing and points toward how the industry might serve the largest patient populations.

Distribution rebuilt alongside the plants

The onshoring push extends past the factory floor. Both companies leaned hard into direct-to-patient channels. Lilly’s LillyDirect shipped orforglipron to patients within days of approval; Novo built out its own direct route. The manufacturers are learning to sell around the traditional pharmacy counter as much as through it, controlling more of the chain from synthesis to doorstep.

Why it matters

The through-line is a bet on permanence. Companies do not commit tens of billions to fixed capacity for a fad. The investments encode a conviction that the obesity market is not a spike but a plateau — a durable, decades-long category worth building irreversible infrastructure to serve.

That conviction has knock-on effects. Domestic capacity could ease future shortages, stabilize supply, and shorten the distance between a manufacturing line and a patient. It also concentrates economic and strategic weight in the hands of the two dominant players, raising the bar for challengers who must match not only the science but the industrial scale.

What it means

For patients, more capacity should mean fewer shortages and steadier access — the shortage years that launched the compounding boom are, in part, what this construction is meant to prevent. For the industry, the factory boom is a statement of belief: that these drugs are here to stay, and that whoever can make the most of them, most reliably, wins.

The molecules get the headlines. The plants decide who can actually deliver them.

Frequently asked questions

Why were GLP-1 drugs in shortage? Demand outran supply, and peptide manufacturing is slow and hard to scale — multi-step synthesis plus specialized sterile fill-finish. New capacity takes years to build, validate, and bring online, so supply could not catch up quickly.

How much are Lilly and Novo investing in U.S. plants? Eli Lilly pledged at least $27 billion in new U.S. manufacturing, and Novo Nordisk around $10 billion, some earmarked to produce its oral semaglutide tablet domestically. The commitments came paired with tariff relief.

Why is peptide manufacturing so difficult? Peptides require assembling amino-acid chains one step at a time, then purifying to pharmaceutical grade and filling precise doses under sterile conditions. Small-molecule drugs like orforglipron are cheaper and simpler to make at scale, which has shaped their lower pricing.

Sources

1. The White House — fact sheet on GLP-1 pricing agreements and associated U.S. manufacturing investments, November 6, 2025.
2. Eli Lilly and Company — U.S. manufacturing investment announcements, 2025–2026.
3. Novo Nordisk A/S — U.S. manufacturing expansion, including oral semaglutide production, 2025–2026.
4. Reuters and Fierce Pharma — reporting on pharmaceutical onshoring and tariff dynamics, 2025–2026.